First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
← catalyst calendarNCT06603844 · readout in 74 d
Sponsored by Corbus Pharmaceuticals Inc. (industry) · CRBP — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
156estimated
Sites
26
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-04 | actual | When the study began enrolling |
| Primary completion | 2026-11-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Interventions
- Drug: CRB-601 monoclonal antibody
- Drug: Anti-PD-1 monoclonal antibody
Primary outcomes
what the primary-completion date above is the date OFOccurance of Dose-limiting toxicities
measured 28 days
Characterize the safety of CRB-601 in combination anti-PD(L)1 therapy
measured 6 months
To evaluate the efficacy of CRB-601 in terms of DCR when administered in combination with anti-PD(L)-1
measured 6 months
Permalink · CRBP's whole pipeline · Catalyst calendar · Every registered study · What changed